1806P - Clinical characteristics and management of small cell lung cancer long survivors

Background

Extensive disease small cell lung cancer (ED-SCLC) accounts for more than 70% of new diagnoses of SCLC with a 5-year survival of 2.8%. A limited portion of ED-SCLC achieved a long term survival but their clinical and biological characteristics are largely unknown. Here we reported baseline clinical characteristics and treatment sequences of a large cohort of long survivors ED-SCLC and we compared them to patients showing a poor outcomes.

Methods

The Epidemio-Strategy and Medical Economics (ESME) lung cancer data platform is a multicenter real-life database using a retrospective data collection process. We selected ED-SCLC patients diagnosed between 2014 and 2021 and having a minimum follow-up of 3 years. Long survivors were defined as having an overall survival (OS) ≥ 24 months. Statistical comparisons were performed by Pearson’s Chi-square, and univariate logistic regression.

Results

We identified 3949 ED-SCLC and 437 long survivors representing 11% of the study population. mOS was 36 months (95%CI 34 to 39) in long survivors and 9 months (95%CI 8.9 to 9.4) in other patients. Compared to other patients, long survivors were enriched in women (45% in long survivors vs 34% in other patients, Odds-Ratio [OR]: 1.60 [1.31 -1.96], p < 0.001), younger patients (63 [IQR: 58,70] vs 66 [IQR: 59,72] years old, OR: 0.97 [0.96-0.98], p < 0.001) and patients with ECOG PS 0-1 at diagnosis (85% vs 58%, OR: 4.05, p

Conclusions

Long survivors represents a small proportion of ED-SCLC characterized by a more indolent disease at diagnosis. Biological characteristics of these patients should be investigated in order to inform clinical research for new therapeutic strategies.

Clinical trial identification

NCT03848052.

Editorial acknowledgement

Legal entity responsible for the study

Unicancer / Institut Curie.

Funding

The ESME LC database receives financial support from industrial partners. Unicancer manages ESME databases independently (i.e. data collection, analysis and publication) and is the sole data controller for data processing.

Disclosure

E. Gobbini: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Institutional, Research Grant: BMS, AstraZeneca; Non-Financial Interests, Principal Investigator: Janssen; Other, Spouse of AstraZeneca employee: AstraZeneca. C. Chouaid: Financial Interests, Personal, Advisory Board: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. D. Debieuvre: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Janssen, Sanofi-Winthrop, Amgen, Roche; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Coordinating PI: Pfizer; Financial Interests, Institutional, Funding: Roche, AstraZeneca, Janssen, MSD, Pfizer, BMS, Lilly, Boehringer Ingelheim, GSK, Chugaï, Chiesi, Takeda, Bayer, Sanofi-Winthrop, Amgen, AbbVie. X. Quantin: Financial Interests, Institutional, Invited Speaker: SANOFI; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Other, Educational support: AstraZeneca. C. Audigier Valette: Financial Interests, Personal, Advisory Board: Roche, BMS, MSD, AstraZeneca, Sanofi, Janssen, Amgen, Biodena care; Financial Interests, Personal, Invited Speaker: Pfizer; Non-Financial Interests, Advisory Role, Scientific committee: IFCT; Non-Financial Interests, Principal Investigator: GFPC; Non-Financial Interests, Member of Board of Directors, Editorial CommitteeLettre du Cancérologue Actualités en Oncologie Thoracique: Edimark; Non-Financial Interests, Member of Board of Directors, President: 3C VAR OUEST. G. Justeau: Non-Financial Interests, Advisory Role: BMS. A. Madroszyk Flandin: Financial Interests, Personal, Advisory Board, board 24/05/23: Janssen; Financial Interests, Personal, Advisory Board, 10/2021: AstraZeneca. O. Bylicki: Financial Interests, Personal, Advisory Board, Expert Board: BMS, Roche, Takeda; Financial Interests, Personal, Other, Travel congress: MSD; Financial Interests, Personal, Advisory Board, expert board: AstraZeneca, janssen; Financial Interests, Personal, Advisory Board, Board: MSD; Financial Interests, Personal, Other, Travel Congress: AstraZeneca. L. Bosquet: Financial Interests, Institutional, Full or part-time Employment, In charge of scientific projects at Unicancer, Health Data and Partnership Department: Unicancer. M. Pérol: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen, AstraZeneca, AbbVie, Anheart Therapeutics, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape; Financial Interests, Personal, Advisory Board, Advisory board: Novocure; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Takeda, Boehringer Ingelheim; Financial Interests, Personal, Steering Committee Member: Roche, Sophiagenetics, PharmaMar, Anheart Therapeutics; Financial Interests, Personal, Other, DMSB: Roche; Financial Interests, Institutional, Local PI: AstraZeneca, Amgen, Roche, AbbVie, Apollomics, Anheart Therapeutics, Innate Pharma, Boehringer Ingelheim, Arrivent Biopharma, Daiichi Sankyo, Bayer; Financial Interests, Steering Committee Member: Lilly. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer Ingelheim Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Family member is an employee: AstraZeneca. All other authors have declared no conflicts of interest.